Retatrutide vs Tirzepatide: How the Two Research Peptides Compare

June 26, 2026

The short answer: retatrutide is a triple incretin receptor agonist acting at GLP-1, GIP and glucagon receptors, whereas tirzepatide is a dual agonist acting at GIP and GLP-1 receptors. Both are synthetic research peptides studied for their roles in metabolic and energy-balance signalling. All materials supplied by Reta Research are for research use only, not for human or veterinary use.

Quick comparison table

Attribute	Retatrutide	Tirzepatide
Receptor targets	GLP-1 / GIP / glucagon	GIP / GLP-1
Class	Triple incretin receptor agonist	Dual incretin receptor agonist
Peptide family	Synthetic incretin-mimetic peptide	Synthetic incretin-mimetic peptide
Research formats at Reta Research	Lyophilised vial; multiple milligram sizes	Lyophilised vial; multiple milligram sizes, including 20 mg
Intended use	Research use only	Research use only

Mechanism: triple vs dual incretin agonism

Incretins are gut-derived signalling molecules that modulate glucose handling and energy metabolism. Both peptides are engineered to engage incretin receptors, but they differ in how many receptor systems they address.

Tirzepatide is designed as a dual agonist, engaging the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. In preclinical models, co-activation of these two receptor systems is of research interest for its combined effects on insulin signalling and satiety-related pathways.

Retatrutide extends this concept to a triple agonist, adding activity at the glucagon receptor alongside GLP-1 and GIP. The glucagon receptor arm is studied in relation to hepatic and energy-expenditure pathways, which is why retatrutide is often described in the literature as a distinct pharmacological class from dual agonists. The practical distinction for researchers is one of receptor breadth: three signalling axes versus two.

What each is studied for in research

Both compounds are of research interest primarily in the context of metabolic and energy-balance biology. In in-vitro and preclinical settings, investigators have examined:

Receptor binding and selectivity — how each peptide engages its target receptors and the relative activity across GLP-1, GIP and, for retatrutide, glucagon receptors.
Downstream signalling — cyclic AMP and related second-messenger responses studied in receptor-expressing cell systems.
Energy-balance models — retatrutide's glucagon-receptor component is of particular research interest for pathways linked to energy expenditure and hepatic lipid handling.
Comparative structure-activity work — dual versus triple agonism as a framework for understanding how added receptor targets alter measured responses.

These research contexts are described here only to characterise scientific interest. Nothing on this page should be read as a therapeutic claim, and neither peptide is intended for human or veterinary use.

Purity, testing and formats at Reta Research

Every peptide we supply is characterised so that researchers can work from a known reference. Both retatrutide and tirzepatide are provided as lyophilised material and are analysed by high-performance liquid chromatography (HPLC) to confirm purity.

Each batch is accompanied by a Certificate of Analysis (COA), and you can review our full testing approach on the Quality Testing page. This batch-level documentation lets you record identity and purity data alongside your experimental results, which is essential for reproducibility. Both peptides are available in a range of milligram formats, including a 20 mg tirzepatide presentation, so you can select a size appropriate to your study design.

Which to choose for your research question

The right choice depends on the receptor systems your work is designed to probe. If your study is concerned specifically with dual GIP and GLP-1 signalling, tirzepatide is the direct match. If your research question involves the additional glucagon-receptor axis — for example, models exploring energy expenditure or hepatic pathways — retatrutide's triple-agonist profile is the relevant tool.

Many laboratories acquire both to run comparative work, using the dual versus triple distinction as an experimental variable. Whichever you select, the shared incretin-mimetic background means the two integrate cleanly into a single comparative protocol. Consult the individual product pages for current formats and batch documentation.

Frequently asked questions

How do the receptor targets of retatrutide and tirzepatide differ?

Retatrutide engages three receptor systems — GLP-1, GIP and glucagon — while tirzepatide engages two, GIP and GLP-1. The defining difference is retatrutide's added glucagon-receptor activity, which places it in a different pharmacological class for research purposes.

Are retatrutide and tirzepatide the same class of peptide?

They share a common background as synthetic incretin-mimetic peptides, but they are classified differently by receptor breadth: tirzepatide is a dual incretin receptor agonist and retatrutide is a triple incretin receptor agonist.

Which peptide is newer?

Retatrutide is the more recently characterised of the two, having emerged as a triple-agonist candidate after dual agonists such as tirzepatide were established in the research literature.